| Drug Name |
Celecoxib |
| Drug ID |
BADD_D00410 |
| Description |
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604]
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124] |
| Indications and Usage |
For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis |
| Marketing Status |
Prescription |
| ATC Code |
L01XX33; M01AH01 |
| DrugBank ID |
DB00482
|
| KEGG ID |
D00567
|
| MeSH ID |
D000068579
|
| PubChem ID |
2662
|
| TTD Drug ID |
D03RTS
|
| NDC Product Code |
70247-006; 42806-720; 43063-967; 72567-001; 16714-731; 59385-055; 67296-1600; 51079-199; 65162-819; 50436-0144; 46708-268; 68788-7735; 80425-0167; 65862-793; 13668-307; 69097-422; 80425-0096; 12598-9531; 69097-423; 12598-9516; 55111-898; 67296-1399; 71335-0868; 60429-460; 71610-283; 57582-032; 61919-360; 29300-373; 68180-398; 0591-3984; 70934-220; 0591-3983; 55289-451; 42571-142; 59762-1518; 51655-253; 68180-399; 62332-140; 60687-436; 57582-213; 68788-7286; 64552-4032; 53104-7533; 42806-722; 76420-009; 71209-056; 70518-1346; 65977-0052; 72189-123; 70934-213; 62704-0046; 59746-563; 77771-157; 0378-7150; 0025-1515; 71205-027; 42571-143; 70518-2748; 80425-0040; 75834-236; 65862-908; 71209-054; 63187-301; 42571-144; 63629-8156; 51927-5063; 55700-613; 13668-441; 53002-1338; 0025-1520; 50090-5178; 69367-302; 60687-447; 75834-237; 55154-7646; 50090-3183; 59762-1515; 0093-7165; 80425-0142; 43063-669; 42806-721; 62332-143; 55154-7645; 0591-3985; 68788-7264; 60505-3847; 60505-3849; 0378-7160; 55700-607; 70518-3204; 60505-3848; 71335-0936; 59762-1516; 69097-420; 0093-7170; 45865-970; 63187-633; 70934-469; 61919-837; 51079-215; 69117-0020; 65862-909; 0615-8338; 50228-156; 75834-239; 68981-025; 68180-396; 68071-4476; 69680-135; 69367-301; 65162-820; 0904-6503; 0378-7170; 52048-1995; 29300-157; 16714-734; 50268-168; 77771-156; 33342-158; 77777-115; 50228-159; 0378-7165; 70247-009; 70247-007; 69117-0021; 50090-5638; 42571-145; 69117-0022; 0093-7166; 70934-026; 51552-1461; 80425-0038; 60760-823; 43063-825; 57582-212; 72969-008; 71209-055; 53002-2338; 13668-310; 42708-016; 71205-020; 80425-0039; 67296-1608; 59746-561; 71610-584; 77771-159; 47621-024; 63187-643; 71335-0292; 0025-1530; 65162-818; 77771-158; 65862-910; 80425-0037; 67296-1345; 75834-238; 63187-562; 71335-2019; 71205-439; 71205-055; 65427-002; 60429-462; 13668-442; 62332-141; 62512-0018; 29300-158; 33342-156; 0025-1525; 68071-4392; 58159-067; 46708-267; 72241-025; 60429-461; 46708-270; 68071-4642; 70518-3292; 59762-1517; 65691-0048; 55289-475; 0904-6502; 50228-157; 57582-214; 61919-043; 69097-421; 71335-1804; 72241-023; 62332-142; 43353-257; 60760-824; 63187-079; 29300-374; 16714-733; 0591-3982; 50228-158; 43744-071; 50090-4789; 71209-057; 46708-838; 33342-155; 16714-732; 59746-564; 49706-1880; 63629-3021; 50268-169; 45865-943; 65162-817; 66651-919; 69117-0023; 72761-022; 71335-1066; 68180-395; 68724-1004; 68071-2626; 70518-2922; 65015-882; 57582-211; 33342-157; 72241-022; 45865-840; 46708-269; 65862-907; 42806-723; 59746-562; 60760-209; 0093-7306; 54245-3392; 70247-008; 61919-682; 60429-459; 72241-024 |
| Synonyms |
Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635 |
